Company / Cash per Share
Lineage Cell Therapeutics, Inc. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.19
FY2025
5-year range
$0.07 / $0.36
FY2021-FY2025
Trend
-29.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash per Share has fluctuated over the past 10 years, ranging from $0.06 in FY2020 to $0.36 in FY2021.
Based on SEC 10-K filings.
0.19 in FY2025 with a 5-year CAGR of +23.9%.
Declined from $0.21 to $0.19 over the past 2 years.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +40.3%
- 5-Year CAGR
- +23.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash per share decreased 29.3% year-over-year.
- Peak cash per share was recorded in FY2021.
- Lowest cash per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.19 | -29.3% |
| FY2024 | $0.26 | +25.6% |
| FY2023 | $0.21 | +211.0% |
| FY2022 | $0.07 | -81.6% |
| FY2021 | $0.36 | +474.3% |
| FY2020 | $0.06 | -65.8% |
| FY2019 | $0.19 | -36.1% |
| FY2018 | $0.29 | +35.1% |
| FY2017 | $0.21 | -34.1% |
| FY2016 | $0.33 | +364.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026